2016 Annual Meeting Presentations

AMP CRS Real World Experience: Americas – Dashawn Usher

AMP CRS Real World Experience: Zimbabwe – Zvichauya Charles Chasakara

Engaging and Recruiting Black MSM (BMSM) in the US – Noshima Darden-Tabb

Community Engagement in a Large Community Randomised Trial: The Case of the HPTN 071 (PopART) Study – Nozizwe Makola, Steve Bulemu and Musonda Simwinga

Engaging PWIDs in a Research Study: HPTN 074 Vietnam – Chu Viet Anh

HPTN 075 Study Overview & External Stakeholder Engagement – Daniel K. Gondwe

Overview of HPTN 075 & Best Practices for Community Engagement with External Stakeholders – Joshua M. Kikuvi

Best Practices for Community Engagement with External Stakeholders: HPTN 075 study – Arthur Ogendo

Community Acceptability of Injections: Experience from HPTN 077 – Steve Mphonda

HIV Prevention Trials Network Community Working Group Plenary: Lessons Learned in HPTN 077 – Fanelesibonge Ntombela

HPTN 082 and PrEP Research in Africa – Sinead Delany-Moretlwe

Injectable Pre-Exposure Prophylaxis for HIV Prevention – Raphael J. Landovitz,

Antibody Mediated HIV Prevention: An Overview – Nyaradzo M Mgodi

HIV Testing Update – Estelle Pinowar-Manning

Population-level Surveillance of Antiretroviral Drug Use – Jessica Fogel

Cross-sectional HCV Incidence Testing – Oliver Laeyendecker

Factors Associated with Recent HIV Testing in Project Accept Sub-Populations: HPTN 043 – Brandon Brown

Community Cultural Norms and Condomless Sexual Behavior Among Men Living with HIV Across Three Continents: HPTN 063 – Dustin Duncan

Associations between gender, race, and HIV risk among injection drug users: A secondary analysis of HPTN 037 – Mandy Hill

Racial Disparities in HIV Prevalence and Composition of Risk Networks among People who Inject Drugs: HPTN 037 – Florence Momplaisir

HIV Transmission Risk Among Transgender Women compared with Cisgender Women and MSM Living with HIV: HPTN 063 – Tonia Poteat

Economic resources and HIV preventive behaviors among school-enrolled young women in rural South Africa: HPTN 068 – Larissa Jennings

Introducing HPTN Modelling Centre Who? What? When? How? – Marie-Claude Boily

Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence – Kate Mitchell

Predicting the individual-level effectiveness of daily and nondaily PrEP based on study results from HPTN 067 ADAPT – Dobromir Dimitrov

Methods for Estimating Underreporting of Risk Behaviors – Jim Hughes

Designing Non-Inferiority Trials when the Noninferiority Margin Depends on Adherence (HPTN 083) – Brett Hanscom

Combining Electronic Pill Records and Self-Reported Data to Identify Adherers and Non-Adherers: A Latent Class Model in HPTN 069 – Ying Qing Chen

How Do You Like Your PrEP? Results from the HPTN 067/ADAPT Study – Robert Grant

Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in Men Who Have Sex With Men (MSM) – Roy Gulick

Uptake and Utilization of PrEP Among Black MSM: Why Race Matters (HPTN 073) – Darrell Wheeler

Cabotegravir as Pre-Exposure Prophylaxis for HIV Prevention – Raphael Landovitz

Antibody Mediated HIV Prevention The AMP Studies – Nyaradzo Mgodi

NIAID: State of the Institute and Priorities in HIV/AIDS Research – Anthony Fauci

HPTN State of the Network: Achievements and Way Forward – Wafaa El-Sadr

Optimizing Treatment for Children and Adolescents: The Power of NOW – Martina Penazzato

Sex and secrecy: Disclosure to intimate partners among YPLWH – Linda-Gail Bekker

HIV in Transgender Populations: Evidence for Action – Tonia Poteat

Male involvement in HIV Prevention Trials: Examples from HPTN071 – Helen Ayles